ACS Librexia (Recruiting)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Event-driven Study to Demonstratethe Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, After a Recent Acute Coronary Syndrome
- Medicine
- BMS-986177
- Population
- ASCVD
- Phase
- III
- Starting year
- 2021